New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:39 EDTSGYPSynergy Pharmaceuticals price target raised to $13 from $7 at Cantor
Cantor increased its target on Synergy after the company reported results from a Phase III trial of its chronic constipation treatment, plecanatide, that the firm views as positive. The firm increased its E.U. and Japanese sales estimates for the drug, and it sees the company as a takeover target. Cantor believes that Synergy has multiple upcoming positive catalysts and it maintains a Buy rating.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:15 EDTSGYPSynergy Pharmaceuticals initiates Phase 3 trial for irritable bowel syndrome
Synergy Pharmaceuticals Inc. initiated the first of two planned pivotal phase 3 clinical trials evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide, once-daily oral tablets, for the treatment of irritable bowel syndrome with constipation. Synergy is also evaluating 3.0 and 6.0 mg doses of plecanatide in two ongoing pivotal phase 3 trials for chronic idiopathic constipation, scheduled to read out top-line results in Q2 and Q3 2015. The pivotal phase 3 trial is expected to enroll approximately 1050 adult patients with IBS-C. The primary efficacy endpoint for this trial is the percentage of patients who are Overall Responders during the 12 week treatment period. Synergy plans to initiate the second pivotal phase 3 IBS-C trial with plecanatide in 1H15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use